New drug shows promise for severe Post-Birth depression in tiny study
NCT ID NCT02285504
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early study tested an experimental drug called SAGE-547 in 4 women with severe postpartum depression. The main goal was to check safety and how the drug works in the body, not to prove it treats depression. Because it was very small and had no comparison group, the results are just a first step.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SAGE-547 (an experimental drug given by IV)
- What this could lead to
- If it works, this could point toward a fast-acting treatment for severe postpartum depression.
- What could go wrong
- This is a very early, tiny study with only 4 people and no placebo group. Results may not apply to others, and safety is still being checked.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POSTPARTUM DEPRESSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sage Investigational Site
Chapel Hill, North Carolina, 27514, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A single day of online therapy could curb postpartum depression
- Online exercise program aims to revive postpartum sexual health
- A headset for depression in pregnancy — science tests a Drug-Free option
- Treating Mom's depression may help Baby's brain
- Heavy bleeding after birth linked to depression and anxiety risk
- Vitamin B6 could be a simple shield against postpartum depression